Unlike many product-oriented startups, which start with deep biological insights in a given therapeutic area, Corgentech Inc. is initially forgoing target discovery and validation and instead scouring the literature for targets for its transcription factor decoy technology.

The company looks for a description of a transcription factor's biological function, and then ascertains the quality of animal models in the target's likely indications. Once this has been done, Corgentech says it can generate preclinical compounds within weeks. Indeed, the company already boasts a Phase III compound - its E2F decoy for peripheral bypass graft failure.